Quarterly Report Q3 2016
Oslo, 11 November 2016 – Navamedic ASA (OSE: NAVA), reported revenues of NOK 65.2 million in the third quarter of 2016 (NOK 61.5 million in Q3 2015), and an EBITDA of NOK 1.8 million (NOK 1.5 million in Q3 2015). The company initiated the long-term strategic partnership with TopRidge Pharma. in the period, with the distribution of Imdur® commencing in the Nordic Markets. The development and commercialisation of Sippi® continues to be on-track.
Gennembrud i dansk depressionsbehandling:
Ny behandling klar til patienter med refraktær depression